Sarepta Therapeutics Inc

NASDAQ:SRPT  
74.58
-0.03 (-0.04%)
Products, Regulatory, Earnings Announcements

Sarepta Announces Results From Ongoing Momentum Study, Phase 2 Clinical Trial Of SRP-5051

Published: 12/07/2020 14:01 GMT
Sarepta Therapeutics Inc (SRPT) - Sarepta Therapeutics Inc - Announced Results From Ongoing Momentum Study, a Phase 2 Clinical Trial of Srp-5051.
Sarepta Therapeutics Inc - Srp-5051 Was Generally Well-tolerated Across All Doses Studied, With No Clinical Or Laboratory Findings Reported.
Sarepta Therapeutics Inc - Results Support Continued Dose Escalation of Srp-5051 and Further Clinical Development.
Revenue is expected to be $153.39 Million
Adjusted EPS is expected to be -$1.71

Next Quarter Revenue Guidance is expected to be $161.66 Million
Next Quarter EPS Guidance is expected to be -$1.86

More details on our Analysts Page.